Plasma Pyrophosphate Imbalance According to Phenotype and Bone Remodelling Alterations in Type 1 Neurofibromatosis - PIRATE-NF1 - (PIRATE)
Neurofibromatosis type 1 (NF1) is a multisystemic genetic disorder associated with frequent tumor, skin, visceral, and bone manifestations. Plexiform neurofibromas (PFNs), whether superficial or deep, affect 20 to 50 percent of patients and are responsible for significant morbidity. Inoperable, symptomatic PFNs can now be treated with targeted therapy (selumetinib) in both children and adults. Furthermore, NF1 patients frequently present with bone abnormalities, such as bone dysplasia, scoliosis, or reduced bone mineral density, suggesting impaired mineralization.
Inorganic pyrophosphate (PPi) is a potent antagonist of bone mineralization. It has been shown in a mouse model of NF1 and in human Schwann cell cultures derived from patients with NF1 (2 cases) that there is activation of genes regulating PPi homeostasis, particularly ANKH and ENPP1.
This study aims to measure plasma PPi levels in a cohort of patients with NF1 from the general population, based on their phenotype-specifically, the presence, location, and characteristics of NFPs-as well as their calcium and phosphorus levels.
研究概览
地位
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Issam BILAL, MS
- 电话号码:+330241356828
- 邮箱:Issam.Bilal@chu-angers.fr
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
40 patients. Age ≥18 years ; Confirmed diagnosis of NF1, based on current clinical and/or molecular criteria.
描述
Inclusion Criteria:
- Age ≥18 years
- Confirmed diagnosis of NF1, based on current clinical and/or molecular criteria
- Consent obtained
Exclusion Criteria:
- Other condition affecting bone mineralization
- Known severe renal insufficiency
- Patient who refuses to participate in the study
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
Diagnosed patients with NF1
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
PPi plasma concentration.
大体时间:Visite 1
|
Visite 1
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Plasma PPI Levels in NF1 patients
大体时间:At the time of the consultation
|
At the time of the consultation
|
|
|
Urine PPI Levels in NF1 patients
大体时间:At the time of the consultation
|
At the time of the consultation
|
|
|
presence of a plexiform neurofibroma in NF1 patients
大体时间:At the time of the consultation
|
At the time of the consultation
|
|
|
presence of bone abnormalities in NF1 patients
大体时间:At the time of the consultation
|
At the time of the consultation
|
|
|
Urinary PPI measurement in newly diagnosed patients with NF1
大体时间:At the time of the consultation
|
At the time of the consultation
|
|
|
Location of plexiform neurofibromas
大体时间:At the time of the consultation
|
At the time of the consultation
|
|
|
Calcium measurement
大体时间:At the time of the consultation
|
Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH) |
At the time of the consultation
|
|
Phosporus measurement
大体时间:At the time of the consultation
|
Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH) |
At the time of the consultation
|
|
Vitamine D Assay
大体时间:At the time of the consultation
|
Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH) |
At the time of the consultation
|
|
Parathyroid hormone (PTH) measurement
大体时间:At the time of the consultation
|
Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH) |
At the time of the consultation
|
|
Treatment with selumetinib
大体时间:Visite 1
|
Visite 1
|
合作者和调查者
调查人员
- 首席研究员:Pauline BOITEZ, MD、University Hospital, Angers
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 49RC26_0384
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.